vs

Side-by-side financial comparison of ESPEY MFG & ELECTRONICS CORP (ESP) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $12.1M, roughly 1.6× ESPEY MFG & ELECTRONICS CORP). ESPEY MFG & ELECTRONICS CORP runs the higher net margin — 23.1% vs -177.4%, a 200.5% gap on every dollar of revenue. On growth, ESPEY MFG & ELECTRONICS CORP posted the faster year-over-year revenue change (-10.8% vs -11.5%). ESPEY MFG & ELECTRONICS CORP produced more free cash flow last quarter ($-4.1M vs $-23.1M). Over the past eight quarters, ESPEY MFG & ELECTRONICS CORP's revenue compounded faster (21.3% CAGR vs -12.2%).

ESPEY MFG & ELECTRONICS CORP is a US-based manufacturer specializing in high-reliability power supplies, power conversion systems and specialized electronic components. It serves aerospace, defense, industrial and transportation sectors, delivering custom solutions for harsh environments to OEMs and government contractors across North America and select global markets.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

ESP vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.6× larger
LAB
$19.6M
$12.1M
ESP
Growing faster (revenue YoY)
ESP
ESP
+0.7% gap
ESP
-10.8%
-11.5%
LAB
Higher net margin
ESP
ESP
200.5% more per $
ESP
23.1%
-177.4%
LAB
More free cash flow
ESP
ESP
$19.0M more FCF
ESP
$-4.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
ESP
ESP
Annualised
ESP
21.3%
-12.2%
LAB

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
ESP
ESP
LAB
LAB
Revenue
$12.1M
$19.6M
Net Profit
$2.8M
$-34.7M
Gross Margin
34.7%
48.5%
Operating Margin
25.3%
-168.5%
Net Margin
23.1%
-177.4%
Revenue YoY
-10.8%
-11.5%
Net Profit YoY
47.0%
-28.8%
EPS (diluted)
$0.99
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESP
ESP
LAB
LAB
Q4 25
$12.1M
Q3 25
$9.1M
$19.6M
Q2 25
$9.6M
$21.8M
Q1 25
$10.3M
$40.8M
Q4 24
$13.6M
Q3 24
$10.4M
$22.1M
Q2 24
$11.6M
$22.5M
Q1 24
$8.3M
$45.5M
Net Profit
ESP
ESP
LAB
LAB
Q4 25
$2.8M
Q3 25
$2.2M
$-34.7M
Q2 25
$2.9M
$-33.5M
Q1 25
$1.7M
$-26.0M
Q4 24
$1.9M
Q3 24
$1.6M
$-26.9M
Q2 24
$1.9M
$-45.7M
Q1 24
$1.0M
$-32.2M
Gross Margin
ESP
ESP
LAB
LAB
Q4 25
34.7%
Q3 25
35.4%
48.5%
Q2 25
39.3%
48.8%
Q1 25
28.6%
48.4%
Q4 24
23.2%
Q3 24
26.8%
54.9%
Q2 24
27.6%
46.1%
Q1 24
25.0%
53.1%
Operating Margin
ESP
ESP
LAB
LAB
Q4 25
25.3%
Q3 25
22.7%
-168.5%
Q2 25
27.4%
-118.1%
Q1 25
17.0%
-80.8%
Q4 24
14.9%
Q3 24
16.5%
-120.9%
Q2 24
18.4%
-134.5%
Q1 24
13.2%
-132.2%
Net Margin
ESP
ESP
LAB
LAB
Q4 25
23.1%
Q3 25
23.9%
-177.4%
Q2 25
30.6%
-153.7%
Q1 25
16.5%
-63.8%
Q4 24
14.0%
Q3 24
15.3%
-122.0%
Q2 24
16.3%
-203.3%
Q1 24
12.5%
-70.6%
EPS (diluted)
ESP
ESP
LAB
LAB
Q4 25
$0.99
Q3 25
$0.76
$-0.09
Q2 25
$1.07
$-0.09
Q1 25
$0.63
$-0.07
Q4 24
$0.71
Q3 24
$0.61
$-0.07
Q2 24
$0.73
$-0.12
Q1 24
$0.40
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESP
ESP
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$17.8M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$53.2M
$399.7M
Total Assets
$85.2M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESP
ESP
LAB
LAB
Q4 25
$17.8M
Q3 25
$22.2M
$129.4M
Q2 25
$18.9M
$158.6M
Q1 25
$13.9M
$150.9M
Q4 24
$8.0M
Q3 24
$4.8M
$210.6M
Q2 24
$4.4M
$269.8M
Q1 24
$5.6M
$287.1M
Total Debt
ESP
ESP
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
ESP
ESP
LAB
LAB
Q4 25
$53.2M
Q3 25
$51.0M
$399.7M
Q2 25
$50.8M
$424.5M
Q1 25
$46.3M
$454.6M
Q4 24
$44.8M
Q3 24
$42.5M
$489.3M
Q2 24
$41.3M
$510.3M
Q1 24
$39.3M
$577.3M
Total Assets
ESP
ESP
LAB
LAB
Q4 25
$85.2M
Q3 25
$84.8M
$539.6M
Q2 25
$79.1M
$557.0M
Q1 25
$72.8M
$579.6M
Q4 24
$60.2M
Q3 24
$57.6M
$681.5M
Q2 24
$56.5M
$708.7M
Q1 24
$53.1M
$777.7M
Debt / Equity
ESP
ESP
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESP
ESP
LAB
LAB
Operating Cash FlowLast quarter
$-2.8M
$-22.2M
Free Cash FlowOCF − Capex
$-4.1M
$-23.1M
FCF MarginFCF / Revenue
-34.1%
-118.1%
Capex IntensityCapex / Revenue
10.9%
4.5%
Cash ConversionOCF / Net Profit
-1.00×
TTM Free Cash FlowTrailing 4 quarters
$11.7M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESP
ESP
LAB
LAB
Q4 25
$-2.8M
Q3 25
$5.7M
$-22.2M
Q2 25
$2.8M
$-20.7M
Q1 25
$11.5M
$-30.3M
Q4 24
$5.4M
Q3 24
$1.4M
$-27.9M
Q2 24
$3.2M
$-39.0M
Q1 24
$1.4M
$-62.5M
Free Cash Flow
ESP
ESP
LAB
LAB
Q4 25
$-4.1M
Q3 25
$4.4M
$-23.1M
Q2 25
$915.3K
$-22.6M
Q1 25
$10.5M
$-35.3M
Q4 24
$4.5M
Q3 24
$724.8K
$-30.1M
Q2 24
$2.6M
$-41.0M
Q1 24
$379.1K
$-63.3M
FCF Margin
ESP
ESP
LAB
LAB
Q4 25
-34.1%
Q3 25
48.7%
-118.1%
Q2 25
9.5%
-103.6%
Q1 25
101.8%
-86.6%
Q4 24
33.0%
Q3 24
6.9%
-136.4%
Q2 24
22.2%
-182.2%
Q1 24
4.6%
-138.9%
Capex Intensity
ESP
ESP
LAB
LAB
Q4 25
10.9%
Q3 25
14.2%
4.5%
Q2 25
19.3%
8.7%
Q1 25
9.3%
12.4%
Q4 24
6.5%
Q3 24
6.4%
10.2%
Q2 24
5.7%
8.6%
Q1 24
12.5%
1.7%
Cash Conversion
ESP
ESP
LAB
LAB
Q4 25
-1.00×
Q3 25
2.64×
Q2 25
0.95×
Q1 25
6.72×
Q4 24
2.82×
Q3 24
0.87×
Q2 24
1.71×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESP
ESP

ASC606$11.3M93%
Other$855.0K7%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons